Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
NCT ID: NCT01147016
Last Updated: 2023-04-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
8 participants
INTERVENTIONAL
2010-07-31
2017-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II clinical trial is studying how well giving laboratory-treated T cells after neoadjuvant chemotherapy works in treating women with stage II or stage III breast cancer undergoing surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT02789657
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00769470
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
NCT00618657
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
NCT00821886
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01275677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To estimate progression-free survival (PFS) in women with stage II-III triple-negative breast cancer without a complete pathologic response (cPR) who receive a regimen of neoadjuvant chemotherapy (chemoT), surgery, and/or irradiation followed by 8 infusions of \~10-15 x 10\^9 Her2Bi-armed activated T cells (ATC) (aATC) given twice per week for 4 weeks in combination with IL-2 (aldesleukin) (300,000 IU/m\^2/day) and GM-CSF (sargramostim) (250 μg/m\^2/twice per week) beginning 3 days before the 1st infusion and ending 1 week after the last infusion (defined as immunotherapy).
II. To estimate the change from baseline (pre immunotherapy \[IT\]) to post-IT in specific cytotoxicity and interferon gamma (IFN-γ) enzyme-linked immunosorbent spots (Elispots) of lymphocytes in the blood directed at breast cancer cells.
III. To investigate if pathologic response and the changes in numbers and proportion of infiltrating cells and cancer stem cells in the tumor at the time of surgery are associated with progressive disease.
OUTLINE:
NEOADJUVANT CHEMOTHERAPY: Patients receive dose-dense AC-T regimen comprising doxorubicin hydrochloride intravenously (IV) and cyclophosphamide IV once every 2 weeks for 4 courses followed by paclitaxel IV once every 2 weeks for 4 courses or paclitaxel IV once weekly for 12 weeks. Or, patients receive TAC regimen comprising docetaxel IV, doxorubicin hydrochloride IV, and cyclophosphamide IV once every 3 weeks for 6 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
IMMUNOTHERAPY: Beginning 3 weeks after the last dose of chemotherapy, patients receive Her2Bi-armed activated T cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin subcutaneously (SC) daily beginning 3 days before the first T cell infusion and ending 1 week after the last infusion.
SURGERY: Patients then undergo surgical resection of the breast 2 weeks later.
After completion of study treatment, patients may be followed up at 1, 3, 6, and 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy
HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month
Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care.
HER2Bi-armed activated T cells
Total of 4 of the T cell infusions intravenously over a period of 1 month.
cyclophosphamide
As prescribed by physician, standard of care.
doxorubicin hydrochloride
As prescribed by physician, standard of care.
paclitaxel
As prescribed by physician, standard of care.
laboratory biomarker analysis
Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
neoadjuvant therapy
As prescribed by physician, standard of care.
therapeutic conventional surgery
As recommended by physician, post immunotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HER2Bi-armed activated T cells
Total of 4 of the T cell infusions intravenously over a period of 1 month.
cyclophosphamide
As prescribed by physician, standard of care.
doxorubicin hydrochloride
As prescribed by physician, standard of care.
paclitaxel
As prescribed by physician, standard of care.
laboratory biomarker analysis
Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
neoadjuvant therapy
As prescribed by physician, standard of care.
therapeutic conventional surgery
As recommended by physician, post immunotherapy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of reproductive potential must agree to use an effective nonhormonal method of contraception during therapy
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and/or Karnofsky PS of \>= 70%
* Diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy
* Palpable primary breast tumor measuring \>= 2.0 cm on physical exam or imaging prior to neoadjuvant chemotherapy
* Patients with stage II-IIIB breast cancer that is HER2-negative by immunohistochemistry (IHC) (0-2+) and fluorescence in situ hybridization (FISH) (HER2/chromosome enumeration probe \[CEP\]17 amplification ratio \< 2.0) who have completed "third generation" neoadjuvant chemoT and planned local treatment (surgery and radiation if indicated); estrogen receptor (ER) or progesterone receptor (PR) status should be negative
* Patients may have lymph node positive or negative disease, as long as they have clinical/pathologic stage II or IIIB breast cancer; patients may have the lymph nodes assessed by any method deemed appropriate by the treating physicians, including pre-neoadjuvant therapy sentinel lymph node biopsy
* Presence of residual disease measuring at least 5mm (as single foci or in aggregate) on final pathology following surgery
* Patients must discontinue sex hormone therapy prior to registration, e.g. birth control pills, hormonal replacement therapy
* Absolute neutrophil count (ANC) must be \>= 1000/mm\^3
* Platelet count must be \>= 100,000/mm\^3
* Hemoglobin must be \>= 9.0 mg/dL
* Total bilirubin must be =\< the upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (\> ULN to 1.5 x ULN) resulting from Gilbert's disease or similar syndrome due to slow conjugation of bilirubin; and
* Alkaline phosphatase must be =\< 2.5 x ULN for the lab
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) must be =\< 1.5 x ULN for the lab
* Alkaline phosphatase and AST/ALT may not both be \> the ULN; for example, if the alkaline phosphatase is \> the ULN but =\< 2.5 x ULN, then the AST/ALT must be =\< the ULN; if the AST/ALT is \> the ULN but =\< 1.5 x ULN, then the alkaline phosphatase must be =\< ULN
* Patients with either skeletal pain or alkaline phosphatase that is \> ULN must have a bone scan showing they do not have metastatic disease; suspicious findings on bone scan must be confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy
* Patients with AST/ALT or alkaline phosphatase \> ULN must have liver imaging that does not demonstrate metastatic disease
* Patients with AST/ALT \> ULN must have negative hepatitis studies
* Patients with stage II disease and clinical suspicion for metastatic disease based on reported symptoms, physical examination findings, or laboratory abnormalities must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes); patients with stage IIIA disease must have staging studies demonstrating no evidence of metastatic disease (with exception of axillary lymph nodes or mammary nodes), even if asymptomatic with normal physical examination and laboratory values; such staging studies must include: chest imaging (chest X-ray, computed tomography \[CT\], or MRI), abdominal/pelvis imaging (CT or MRI), and bone imaging (bone scan or positron emission tomography \[PET\]-scan); abnormalities that are indeterminate and too small to biopsy should be followed with further imaging, as appropriate, but do not exclude patients from the study; abnormalities that are suspicious and large enough to biopsy exclude patients from the study, unless a biopsy is performed and is negative for metastatic disease
* Serum creatinine =\< 1.5 x ULN for the lab
* Pre-entry core biopsy with sufficient material for correlative studies
* Left Ventricular Ejection Fraction (LVEF) \>= 45 % (by multigated acquisition scan \[MUGA\] or echocardiography)
Exclusion Criteria
* Tumors clinically staged as anyT with N3 disease or unresectable disease
* Evidence of disease progression on neoadjuvant chemo T
* Definitive evidence of metastatic disease with exception of axillary lymph nodes or mammary nodes
* Synchronous bilateral breast cancer (invasive or ductal carcinoma in situ \[DCIS\])
* Treatment with biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entry
* Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. within 2 weeks prior to the collection of cells
* Prior history of invasive breast cancer (patients with a history of DCIS or lobular carcinoma in situ \[LCIS\] are eligible)
* Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by the physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell or squamous cell carcinoma of the skin
* Known cardiac disease which precludes their ability to receive planned treatments:
* Angina pectoris that requires the use of anti-anginal medication
* History of documented congestive heart failure
* Serious cardiac arrhythmia requiring medication
* Severe conduction abnormality
* Valvular disease with documented cardiac function compromise; and
* Uncontrolled hypertension defined as blood pressure (BP) that is consistently \> 150/90 on antihypertensive therapy at the time of registration (Patients with hypertension that is well controlled on medication are eligible)
* History of myocardial infarction (MI) documented by elevated cardiac enzymes with persistent regional wall motion abnormality on assessment of left ventricular (LV) function (patients with history of MI must have an echo instead of/in addition to a MUGA to evaluate LV wall motion)
* Symptomatic peripheral vascular disease
* Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up
* Chronic ongoing oral steroid use at the time of registration for any condition (such as asthma, rheumatoid arthritis, etc)
* Administration of any investigational agents within 30 days before study entry
* Pregnancy or lactation at the time of registration
* Psychiatric or addictive disorders or other conditions that in the opinion of the investigators would preclude the patient from complying with the study protocol
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Barbara Ann Karmanos Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abhinav Deol
Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amy Weise, M.D.
Role: PRINCIPAL_INVESTIGATOR
Barbara Ann Karmanos Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WSU-2010-056
Identifier Type: OTHER
Identifier Source: secondary_id
2010-056(b)
Identifier Type: -
Identifier Source: org_study_id
NCT01658969
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.